| Title |
Economic implications of using bendamustine, alemtuzumab, or chlorambucil as a first-line therapy for chronic lymphocytic leukemia in the US: a cost-effectiveness analysis
|
|---|---|
| Published in |
ClinicoEconomics and Outcomes Research: CEOR, April 2014
|
| DOI | 10.2147/ceor.s55095 |
| Pubmed ID | |
| Authors |
Thitima Kongnakorn, James A Sterchele, Christopher G Salvador, Denis Getsios, Mkaya Mwamburi |
X Demographics
The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 2 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Practitioners (doctors, other healthcare professionals) | 2 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 22 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 1 | 5% |
| Unknown | 21 | 95% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 6 | 27% |
| Student > Master | 3 | 14% |
| Student > Bachelor | 2 | 9% |
| Student > Ph. D. Student | 2 | 9% |
| Other | 2 | 9% |
| Other | 3 | 14% |
| Unknown | 4 | 18% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 9 | 41% |
| Pharmacology, Toxicology and Pharmaceutical Science | 2 | 9% |
| Social Sciences | 2 | 9% |
| Economics, Econometrics and Finance | 1 | 5% |
| Arts and Humanities | 1 | 5% |
| Other | 1 | 5% |
| Unknown | 6 | 27% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 01 April 2014.
All research outputs
#20,567,353
of 25,837,817 outputs
Outputs from ClinicoEconomics and Outcomes Research: CEOR
#400
of 530 outputs
Outputs of similar age
#170,519
of 241,559 outputs
Outputs of similar age from ClinicoEconomics and Outcomes Research: CEOR
#13
of 16 outputs
Altmetric has tracked 25,837,817 research outputs across all sources so far. This one is in the 18th percentile – i.e., 18% of other outputs scored the same or lower than it.
So far Altmetric has tracked 530 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 11.9. This one is in the 15th percentile – i.e., 15% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 241,559 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 25th percentile – i.e., 25% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 16 others from the same source and published within six weeks on either side of this one. This one is in the 6th percentile – i.e., 6% of its contemporaries scored the same or lower than it.